Cerevel Therapeutics Holdings Inc expected to post a loss of 59 cents a share - Earnings Preview

Cerevel Therapeutics Holdings

16/02/2024 13:55

* Cerevel Therapeutics Holdings Inc  CERE.OQ   CERE.O  is
expected
to show no change in quarterly revenue when it reports 
results on February 20 (estimated) for the period ending
December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Cerevel Therapeutics
Holdings
Inc is for a loss of 59 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 9
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Cerevel
Therapeutics Holdings Inc is $45.00​, above​ its last closing
price of $42.93. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.64       -0.63      -0.61     Beat    3.5
 Jun. 30 2023  -0.64       -0.65      -0.63     Beat    2.9
 Mar. 31 2023  -0.69       -0.67      -0.67     Met     0.6​
 Dec. 31 2022  -0.64       -0.64      -0.59     Beat    8
 ​​Sep.        -0.62       -0.62      -0.66     Missed  -7.1
 30 2022                                                
 Jun. 30 2022  -0.50       -0.48      -0.62     Missed  -30.3​
 Mar. 31 2022  -0.43       -0.42      -0.46     Missed  -8.2
 Dec. 31 2021  -0.41       -0.41      -0.40     Beat    1.6
 This summary was machine generated February 16 at 13:55 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)